Molecular Docking and Simulation-Based Exploration of Niclosamide as a Potential Inhibitor of the p62 ZZ Domain
Open Access
Abstract
Acute myeloid leukemia (AML) remains a therapeutic challenge due to complex oncogenic networks, including the often-undruggable MYC pathway. Here, we present an integrated in silico framework combining transcriptomic analysis, machine learning, and molecular dynamics (MD) simulations to explore potential therapeutic approaches targeting vault RNA1-1 (VTRNA1-1) in AML. RNA-seq profiling revealed that VTRNA1-1 depletion is associated with a profound disruption of the MYC and FOXM1 regulatory axes. To highlight compounds capable of recapitulating this transcriptomic signature, we developed a machine learning pipeline utilizing a Random Forest classifier trained on a fully compiled L1000FWD database subset. Virtual screening of approved drugs predicted the anthelmintic niclosamide as a top candidate (98.17% mimic probability). Explainable AI further rationalized this prediction by highlighting specific fragments within niclosamide’s salicylanilide core. Furthermore, a 200 ns MD simulation indicated favorable computational stability of niclosamide bound to the p62 (SQSTM1) ZZ domain. The complex showed rapid structural convergence (ligand RMSD plateauing at 1.65 nm) without dissociation, while maintaining strict receptor compactness (steady Radius of Gyration and solvent-accessible surface area) and a persistent interaction network of ~73 close atomic contacts. These findings suggest that niclosamide may function as a stable physical “lid” over the p62 ZZ domain, occluding its N-degron-binding cleft. Taken together, our computational framework highlights niclosamide as a promising candidate for AML drug repurposing, providing a hypothesis-generating foundation that warrants rigorous experimental validation.Keywords
Funding Information
- Japan Society for the Promotion of Science (24K18664)
- Kurozumi Medical Research Foundation
This publication has 39 references indexed in Scilit:
- A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathwayBiochemical Pharmacology, 2025
- Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseasesEuropean Journal of Medicinal Chemistry, 2025
- Serum vault RNA1-1 levels reflect blood cells and bone marrowMolecular and Cellular Probes, 2025
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)Current Oncology Reports, 2024
- Vault RNAs (vtRNAs): Rediscovered non-coding RNAs with diverse physiological and pathological activitiesGenes & Diseases, 2024
- MYC as a target for cancer treatmentCancer Treatment Reviews, 2021
- Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemiaDrug Resistance Updates, 2020
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challengesBlood Reviews, 2019
- Selective Autophagy: RNA Comes from the Vault to Regulate p62/SQSTM1Current Biology, 2019
- The Small Non-coding Vault RNA1-1 Acts as a Riboregulator of AutophagyCell, 2019